Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile

NEW YORK, Jan. 11, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Sanofi-Aventis: PharmaVitae Profile

http://www.reportlinker.com/p0201760/Sanofi-Aventis-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

* Gain insight into Sanofi-Aventis's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for Sanofi-Aventis over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

* Benchmark Sanofi-Aventis's performance against key rivals in the prescription pharmaceutical sector.* Analyse the positioning of the company as a diversified healthcare player with an enhanced focus on the vaccine, generic and consumer markets.* Assess how the genericization of blockbusters Plavix, Eloxatine, Taxotere, Stilnox/Ambien and Lovenox is expected to significantly impact growth.

To order this report:

: Sanofi-Aventis: PharmaVitae Profile

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…